BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-72. [PMID: 25173358 DOI: 10.1007/s00467-014-2944-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 2017;36:2859-67. [PMID: 28905254 DOI: 10.1007/s10067-017-3823-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
2 Wenderfer SE, Chang J, Hicks MJ. Approach to Classification and Management of Childhood-Onset Lupus Nephritis. Curr Pediatr Rep 2020;8:26-35. [DOI: 10.1007/s40124-020-00207-8] [Reference Citation Analysis]
3 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM. Complement-mediated 'bystander' damage initiates host NLRP3 inflammasome activation. J Cell Sci 2016;129:1928-39. [PMID: 27006116 DOI: 10.1242/jcs.179291] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
5 Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016;8:6625. [PMID: 27781079 DOI: 10.4081/hr.2016.6625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Trimarchi H, Coppo R. COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment? J Nephrol 2020;33:1119-20. [PMID: 32996110 DOI: 10.1007/s40620-020-00859-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
8 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
9 Ring T, Pedersen BB, Salkus G, Goodship TH. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489-91. [PMID: 26413271 DOI: 10.1093/ckj/sfv076] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
10 Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Adv Exp Med Biol 2015;865:19-42. [PMID: 26306441 DOI: 10.1007/978-3-319-18603-0_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
11 Chighizola CB, Lonati PA, Trespidi L, Meroni PL, Tedesco F. The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. Front Immunol 2020;11:2084. [PMID: 32973817 DOI: 10.3389/fimmu.2020.02084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-495. [PMID: 28669995 DOI: 10.1038/nrneph.2017.85] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 21.0] [Reference Citation Analysis]
13 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
14 Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J 2019;12:196-205. [PMID: 30976396 DOI: 10.1093/ckj/sfy035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
16 Song D, Guo WY, Wang FM, Li YZ, Song Y, Yu F, Zhao MH. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis. Am J Med Sci 2017;353:247-57. [PMID: 28262211 DOI: 10.1016/j.amjms.2017.01.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
17 Bermea RS, Sharma N, Cohen K, Liarski VM. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol 2016;22:320-3. [PMID: 27556240 DOI: 10.1097/RHU.0000000000000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
18 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
19 Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study. Medicine (Baltimore) 2016;95:e3595. [PMID: 27149490 DOI: 10.1097/MD.0000000000003595] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
20 Chen SF, Chen M. Complement Activation in Progression of Chronic Kidney Disease. Adv Exp Med Biol 2019;1165:423-41. [PMID: 31399977 DOI: 10.1007/978-981-13-8871-2_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hanna RM, Henriksen K, Kalantar-Zadeh K, Ferrey A, Burwick R, Jhaveri KD. Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers. Adv Chronic Kidney Dis 2022;29:149-160.e1. [PMID: 35817522 DOI: 10.1053/j.ackd.2021.11.006] [Reference Citation Analysis]
23 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
24 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
25 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175-87. [DOI: 10.1016/j.molimm.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Rojas-Rivera J, Fernández-Juárez G, Praga M. Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease? Clin Kidney J 2015;8:477-81. [PMID: 26413269 DOI: 10.1093/ckj/sfv095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
28 Chehade H, Rotman S, Frémeaux-Bacchi V, Aubert V, Sadallah S, Sifaki L, Salomon R, Pascual M. Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody. Am J Kidney Dis 2016;68:944-8. [PMID: 27683044 DOI: 10.1053/j.ajkd.2016.06.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Seminars in Immunology 2019;45:101339. [DOI: 10.1016/j.smim.2019.101339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
30 Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, Terence Cook H, Cairns TD. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015;54:2286-8. [PMID: 26316577 DOI: 10.1093/rheumatology/kev307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
31 Bhargava R, Li H, Tsokos GC. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr Opin Rheumatol 2022. [PMID: 35797522 DOI: 10.1097/BOR.0000000000000887] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrologia 2017;37:478-91. [PMID: 28946961 DOI: 10.1016/j.nefro.2017.01.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
33 Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall’era M. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 2017;37:1249-55. [DOI: 10.1007/s00296-017-3686-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
34 Birmingham DJ, Hebert LA. The Complement System in Lupus Nephritis. Seminars in Nephrology 2015;35:444-54. [DOI: 10.1016/j.semnephrol.2015.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
35 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice. BMC Nephrol 2019;20:424. [PMID: 31752725 DOI: 10.1186/s12882-019-1599-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017;13:538-47. [DOI: 10.1038/nrrheum.2017.125] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 19.0] [Reference Citation Analysis]
38 Bhargava R, Tsokos GC. The immune podocyte. Curr Opin Rheumatol 2019;31:167-74. [PMID: 30562182 DOI: 10.1097/BOR.0000000000000578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
39 Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus 2021;:9612033211027938. [PMID: 34192954 DOI: 10.1177/09612033211027938] [Reference Citation Analysis]
40 Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells 2021;10:148. [PMID: 33451011 DOI: 10.3390/cells10010148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
42 Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant 2017;32:i57-64. [PMID: 28391332 DOI: 10.1093/ndt/gfw228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
43 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2018;2:2090-4. [PMID: 30131343 DOI: 10.1182/bloodadvances.2018019596] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
45 Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 2017;56:i32-45. [PMID: 28013203 DOI: 10.1093/rheumatology/kew407] [Cited by in Crossref: 16] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
46 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
47 Cao M, Ferreiro T, Leite BN, Pita F, Bolaños L, Valdés F, Alonso A, Vázquez E, Mosquera J, Trigás M, Rodríguez S. Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Rep 2017;6:91-7. [PMID: 28509134 DOI: 10.1007/s13730-017-0251-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
48 Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore) 2017;96:e6056. [PMID: 28178155 DOI: 10.1097/MD.0000000000006056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
49 Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol 2019;10:672. [PMID: 31001274 DOI: 10.3389/fimmu.2019.00672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
50 Ham YJ, Nicklason E, Wightman T, Akom S, Sandhu K, Harraka P, Colville D, Catran A, Barit D, Langsford D, Pianta T, Foote A, Buchanan R, Mack H, Savige J. Retinal drusen are more common and larger in SLE with renal impairment. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.01.1063] [Reference Citation Analysis]
51 Picard C, Lega J, Ranchin B, Cochat P, Cabrera N, Fabien N, Belot A. Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus. Pediatr Nephrol 2017;32:1537-45. [DOI: 10.1007/s00467-017-3646-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 2019;49:74-83. [PMID: 30598332 DOI: 10.1016/j.semarthrit.2018.11.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]